Lifecore Biomedical, Inc. De (LFCR) Cash from Investing Activities (2010 - 2025)

Lifecore Biomedical's Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$2.1 million for Q2 2025.

• In Q2 2025, Cash from Investing Activities rose 22.71% year-over-year to -$2.1 million; the TTM figure through May 2025 stood at -$6.4 million (up 65.13% YoY), while the FY2025 annual figure was -$6.4 million, up 65.13% from the prior year.
• Cash from Investing Activities was -$2.1 million for Q2 2025 at Lifecore Biomedical, down from $1.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $65.2 million in Q1 2022 to a low of -$17.5 million in Q2 2022.
• Historically, Cash from Investing Activities has averaged $1.8 million across 5 years, with a median of -$3.6 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Cash from Investing Activities soared 139607.41% in 2021, then slumped 2136.28% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$5.4 million in 2021, then rose by 29.06% to -$3.8 million in 2022, then dropped by 10.73% to -$4.3 million in 2023, then soared by 42.74% to -$2.4 million in 2024, then rose by 14.06% to -$2.1 million in 2025.
• The last three Cash from Investing Activities figures came in at -$2.1 million (Q2 2025), $1.5 million (Q1 2025), and -$2.4 million (Q4 2024), per Business Quant data.